Pharmaceuticals, Biotechnology and Life Sciences
Zealand Pharma has announced a $10 million milestone payment following Sanofi’s announcement of European Commission marketing authorization in Europe for…
The European Commission has cleared Sanofi’s Suliqua in combination with metformin, type 2 diabetes treatment, for European adult patients.
Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.
Sanofi and Regeneron Pharmaceuticals are going to will appeal the injunction granted on Friday by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent in the U.S. during the term of two Amgen patents.
Sanofi’s Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
France’s Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application…
Two prominent U.S. lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co, Merck…
Sanofi and Regeneron Pharmaceuticals have announced the FDA issued a Complete Response Letter (CRL) regarding…